Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Multiple Sclerosis, Relapsing-Remitting

ClinicalTrials.gov lists 612 trials for Multiple Sclerosis, Relapsing-Remitting or a narrower condition beneath it. Biogen has the most among industry and government lead sponsors, with 78.

MeSH D020529 Nervous System Diseases C10 C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 47 Phase 1/2 Phase 1/2 18 Phase 2 Phase 2 97 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 95 Phase 4 Phase 4 81 Not applicable Not applicable 112 Observational Observational 159 Phase 1 Phase 1 47 Phase 1/2 Phase 1/2 18 Phase 2 Phase 2 97 Phase 2/3 Phase 2/3 3 Phase 3 Phase 3 95 Phase 4 Phase 4 81 Not applicable Not applicable 112 Observational Observational 159

Trials per phase (log scale)

612 of the 612 trials are tagged with Multiple Sclerosis, Relapsing-Remitting itself; the rest are tagged with a narrower condition beneath it.

Get the Multiple Sclerosis, Relapsing-Remitting report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Multiple Sclerosis, Relapsing-Remitting trials start? (29)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 37

1994: 1 trials (Phase 4 1) 1998: 1 trials (Phase 1 1) 1999: 3 trials (Phase 4 1, Phase 3 1, Phase 2 1) 2001: 2 trials (Phase 3 2) 2002: 6 trials (Phase 3 1, Phase 2 4, Phase 1/2 1) 2003: 20 trials (Observational 2, Not applicable 1, Phase 4 5, Phase 3 2, Phase 2 6, Phase 1/2 1, Phase 1 3) 2004: 11 trials (Phase 4 5, Phase 3 1, Phase 2/3 1, Phase 2 4) 2005: 15 trials (Observational 5, Phase 4 3, Phase 3 4, Phase 2 2, Phase 1 1) 2006: 22 trials (Observational 5, Not applicable 1, Phase 4 1, Phase 3 7, Phase 2/3 1, Phase 2 4, Phase 1 3) 2007: 17 trials (Observational 4, Phase 4 1, Phase 3 5, Phase 2 4, Phase 1/2 2, Phase 1 1) 2008: 17 trials (Observational 9, Phase 4 2, Phase 3 3, Phase 2 2, Phase 1 1) 2009: 27 trials (Observational 10, Not applicable 1, Phase 4 3, Phase 3 4, Phase 2 7, Phase 1 2) 2010: 29 trials (Observational 3, Not applicable 1, Phase 4 4, Phase 3 5, Phase 2 8, Phase 1/2 1, Phase 1 7) 2011: 29 trials (Observational 4, Not applicable 2, Phase 4 7, Phase 3 5, Phase 2 7, Phase 1 4) 2012: 23 trials (Observational 8, Not applicable 4, Phase 4 6, Phase 3 4, Phase 1/2 1) 2013: 33 trials (Observational 5, Not applicable 5, Phase 4 3, Phase 3 7, Phase 2 8, Phase 1/2 1, Phase 1 4) 2014: 27 trials (Observational 3, Not applicable 5, Phase 4 8, Phase 3 4, Phase 2 3, Phase 1/2 1, Phase 1 3) 2015: 37 trials (Observational 8, Not applicable 4, Phase 4 7, Phase 3 4, Phase 2 5, Phase 1/2 5, Phase 1 4) 2016: 18 trials (Observational 5, Not applicable 2, Phase 4 4, Phase 3 5, Phase 2 2) 2017: 33 trials (Observational 9, Not applicable 6, Phase 4 6, Phase 3 5, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 2) 2018: 22 trials (Observational 9, Not applicable 6, Phase 3 2, Phase 2 3, Phase 1 2) 2019: 26 trials (Observational 5, Not applicable 7, Phase 4 3, Phase 3 7, Phase 2 4) 2020: 27 trials (Observational 5, Not applicable 12, Phase 4 3, Phase 3 3, Phase 2 1, Phase 1 3) 2021: 30 trials (Observational 20, Not applicable 1, Phase 4 1, Phase 3 2, Phase 2 5, Phase 1 1) 2022: 27 trials (Observational 10, Not applicable 6, Phase 4 3, Phase 3 3, Phase 2 3, Phase 1/2 2) 2023: 33 trials (Observational 11, Not applicable 15, Phase 4 1, Phase 3 2, Phase 2 2, Phase 1/2 1, Phase 1 1) 2024: 29 trials (Observational 12, Not applicable 11, Phase 4 1, Phase 3 1, Phase 2 2, Phase 1 2) 2025: 20 trials (Observational 4, Not applicable 8, Phase 4 2, Phase 3 4, Phase 2 1, Phase 1 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 24
2025 20
2024 29
2023 33
2022 27
2021 30
2020 27
2019 26
2018 22
2017 33

Showing 10 of 29 earlier years.

Start your 14-day trial Email me all 29 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 29 trials starting in 2026 and about 26 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 53 trials still running at the 2026-10-09 snapshot; registered median of 27 months across 427 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Multiple Sclerosis, Relapsing-Remitting trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 47
Phase 1/2 18
Phase 2 97
Phase 2/3 3
Phase 3 95
Phase 4 81
Not applicable 112
Observational 159

How many Multiple Sclerosis, Relapsing-Remitting trials are recruiting? (9)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 15
Recruiting 49
Enrolling by invitation 4
Active, not recruiting 29
Completed 366

Showing 5 of 9 statuses.

Start your 14-day trial Email me all 9 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Multiple Sclerosis, Relapsing-Remitting trials? (9)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Biogen 78
Novartis Pharmaceuticals 30
Merck KGaA, Darmstadt, Germany 26
Bayer 17
Teva Branded Pharmaceutical Products R&D, Inc. 12

Showing 5 of 9 sponsors.

Start your 14-day trial Email me all 9 sponsors as a PDF

Which drugs are being tested for Multiple Sclerosis, Relapsing-Remitting? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Dimethyl Fumarate 37
METHYLPREDNISOLONE 12
RITUXIMAB 7
Peginterferon Beta-1a 6

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
SC interferon beta-1a 43
fingolimob (FTY) 27
natalizumab SC 26
Copaxone-Teva 22
SC interferon beta-1b 21

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Multiple Sclerosis, Relapsing-Remitting trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Multiple sclerosis relapse 1,390 42
Multiple Sclerosis Relapse 273 7
MULTIPLE SCLEROSIS RELAPSE 261 6
Pneumonia 142 38
Urinary tract infection 125 32

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Multiple Sclerosis, Relapsing-Remitting? (774)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Annual 12-Week Dosing Gap of Natalizumab: Clinical Efficacy, Blood Biomarkers, and CSF Cell Composition. Annals of clinical and translational neurology 2026 Yes
Safety and efficacy of opicinumab in participants with relapsing multiple sclerosis (AFFINITY Part 1): A randomized, controlled, phase 2 trial. Multiple sclerosis (Houndmills, Basingstoke, England) 2026 Yes
Efficacy and tolerability of metformin as an adjuvant therapy in patients with relapse-remitting multiple sclerosis receiving interferon Beta 1a: A randomized pilot trial. Journal of neuroimmunology 2026 Yes
Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis. Inflammatory bowel diseases 2025 Yes
Performance of Composite Endpoints Defining Progression Independent of Relapse Activity in Multiple Sclerosis. Annals of clinical and translational neurology 2025 Yes

Showing 5 of 774 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages